Home > Productos > Nutraceuticals > Pomolive

Nutraceuticals

Logos_All_BrandedIngredients_2023_Pomolive-1-removebg-preview

Apple & Olive Extract that combats metabolic syndrome.

Standardised to apple-derived polyphenols and triterpenic compounds from olives.

Request a quote and sample
pomolive-features-bg

Decreases adipose tissue and increases muscular mass, therefore could be used in treatment to reduce fat deposits in overweight and obese individuals.

Reduces waist circumference, an important predictive cardiovascular risk marker.

Lowers basal glycemia, protecting against insulin resistance.

Diminishes elevated triglycerides that herald the onset of atherosclerosis.

sindrome-metabolico

Metabolic Syndrome

Metabolic Syndrome (MS) denotes a cluster of conditions that increase the risk of heart disease and other health issues, such as diabetes and stroke probability.

It has been estimated that approximately 10-30% of the world’s adult population has MS. In the United States and Europe the prevalence is higher, ranging from 22-24%.

beneficios-bg

Preclinical studies

Our preclinical studies show the synergistic effect of apple and olive combined is significantly greater on glucose and lipid profile than the ingredients by themselves.

Lumbar adipose tissue

Basal serum glucose

Triglycerides serum levels

Figure 1. Lumbar adipose tissue in obese mice (ob/ob, OB) and obese mice treated with POMOLIVE (OB+POMOLIVE) after 6 weeks of treatment. * p<0.05 vs. Obese.

Lumbar adipose tissue

Pomolive significantly reduces increased lumbar adipose tissue in obese mice

The presence of fat deposits is significant in explaining the link between the distribution of body fat and the occurrence of cardio-metabolic risk factors and coronary artery disease.

Figure 2. Basal glycemia in obese mice (ob/ob, OB) and obese mice treated with POMOLIVE (OB+POMOLIVE) after 6 weeks of treatment. * p<0.05 vs. Obese

Basal serum glucose

Pomolive normalised increased basal serum glucose levels in obese mice

Type 2 diabetes is a progressive disease characterised by hyperglycemia preceded by insulin resistance or diminished sensitivity of β-cell to insulin caused by various metabolic anomalies, including obesity

Figure 3. Serum triglycerides in obese mice (ob/ob, OB) and obese mice treated with POMOLIVE (OB+POMOLIVE) after 6 weeks of treatment. * p<0.05 vs. Obese.

Triglycerides serum levels

Pomolive reduced triglycerides serum levels in obese mice

During periods of increased energy demand, triglycerides stored in adipose tissues are immediately released via lipolysis.

Lipolysis is also involved in the pathogenesis of metabolic disorders; recent studies in humans have underscored its role in disease states such as obesity-induced insulin resistance.

Clinical Studies

Apple consumption is associated with a lower risk for diabetes.

Olive has shown hypolipidemic effects by lowering serum cholesterol and triglycerides levels.

Pomolive’s efficacy in treating metabolic syndrome was verified in a prospective, randomised, double-blind, placebo-controlled study. Pomolive’s efficacy was proven in lowering obesity-related parameters and increased muscle mass, as well as controlling serum glucose.

The study was conducted on 60 subjects. Pomolive was administrated on a daily dose of 500 mg (250mg twice daily) for 8 weeks. The most representative results are summarised below.

  • Pomolive lowered body weight
  • Pomolive reduced body mass index
  • Pomolive produced adipose tissue loss
  • Pomolive stimulated Muscular mass gain
  • Pomolive induced waist circumference reduction
  • Pomolive controlled serum glucose
bg-left
pomolive-full pomolive-full

Figure 4. Body weight, Kg (A), Body mass index (BMI), Kg/m2 (B), Adipose tissue,% (C), Muscular mass gain, % (D), Waist circumference, cm (E) and Serum glucose, % (F) in Placebo and POMOLIVE treated subjects after 8 weeks of treatment. * p<0.05 vs Placebo.

References: Alberti KG et al. Circulation, 2009. Alberti KG et al. Lancet, 2005. Arner P et al. Trends in Endocrinology and Metabolism, 2014. Beltrán-Sánchez et al. J Am Coll Cardiol, 2013. Ford ES et al. J Diabetes, 2010. Luna-Luna M et al. Archives of Medical Research, 2015. Mulè et al. World Journal of Cardiology, 2014. Rask-Madsen C et al. Arterioscler Thromb Vasc Biol., 2012.

Request a quote and sample

Would you like to request an estimate or samples of our products? Send us your request on this simple form and our team will get in touch with you to answer any questions you might have and to find out more about your needs.

Fields with (*) are required

"*" indicates required fields

This field is hidden when viewing the form
cta-bg cta-bg

Subscribe to our Newsletter

Receive the latest news on Natac in your email